Siplizumab

3 trials Orphan designation

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

0 Recruiting

2 Completed trials

1 Sponsors

5 Countries

Phase II

Phase II: 3

Oversight events:

2 temporary halts 1 corrective measure across 2 trials

View oversight register →

Indications tested

Type 1 diabetes mellitus 1

Sponsors using this IMP

All trials

3 total

A study to investigate whether treatment with a siplizumab-based regimen can induce allogeneic tolerance in liver transplant recipients. Halted

2023-508397-29-00 Phase II 1 country Itb-Med AB
A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patient… Ended

2023-506837-31-00 Phase II 4 countries Itb-Med AB
A 12-Month Clinical Research Study to evaluate a new investigational medication (siplizumab) compared to another medication (anti thymocyte … Ended

2023-507895-36-00 Phase II 3 countries Itb-Med AB

Showing 1–3 of 3 trials

← All drugs A–Z